Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Children's Advil Allergy Sinus Patent Expiration

Children's Advil Allergy Sinus is a drug owned by Haleon Us Holdings Llc. It is protected by 1 US drug patent filed in 2019 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 25, 2024. Details of Children's Advil Allergy Sinus's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 Pharmaceutical suspension composition
May, 2024

(6 months ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Children's Advil Allergy Sinus is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Children's Advil Allergy Sinus's family patents as well as insights into ongoing legal events on those patents.

Children's Advil Allergy Sinus's Family Patents

Children's Advil Allergy Sinus has patent protection in a total of 8 countries. It's US patent count contributes only to 38.5% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Children's Advil Allergy Sinus.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Children's Advil Allergy Sinus's generic launch date based on the expiry of its last outstanding patent is estimated to be May 25, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Children's Advil Allergy Sinus Generics:

There are no approved generic versions for Children's Advil Allergy Sinus as of now.





About Children's Advil Allergy Sinus

Children'S Advil Allergy Sinus is a drug owned by Haleon Us Holdings Llc. Children'S Advil Allergy Sinus uses Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride as an active ingredient. Children'S Advil Allergy Sinus was launched by Haleon Us Holdings in 2004.

Approval Date:

Children's Advil Allergy Sinus was approved by FDA for market use on 24 February, 2004.

Active Ingredient:

Children's Advil Allergy Sinus uses Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride ingredient

Dosage:

Children's Advil Allergy Sinus is available in suspension form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
1MG/5ML;100MG/5ML;15MG/5ML SUSPENSION Over the counter ORAL